✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Savara Inc. (SVRA) Shares Are Taking Off. Here’s What’s Coming

Savara Inc. (NASDAQ:SVRA) is one of the 10 Stocks Posting Monster Gains Amid Market Downfall.

Savara extended its winning streak to a third consecutive day on Thursday, surging 10.38 percent to close at $5.21 apiece, as investors began positioning portfolios ahead of the Food and Drug Administration’s (FDA) decision on its treatment candidate for autoimmune pulmonary alveolar proteinosis (PAP).

The FDA is expected to announce its decision on Savara Inc.’s biologics license application for Molbreevi on Sunday, November 22.

Photo by Tima Miroshnichenko on Pexels

Earlier this year, the company said that it is focusing on the potential launch of Molbreevi in the US, representing its nearest-term opportunity, supported by a strong balance sheet to ensure commercial readiness. It is also awaiting decisions from regulators in Europe and the UK.

Molbreevi holds the potential to tap more than $2 billion in total addressable market in the US alone, with an estimated 5,500 patients and pricing power of $400,000 to $500,000 per year, as the treatment targets a rare disease with limited therapeutic alternatives.

Molbreevi aside, Savara Inc. holds a strong buy rating from eight analysts covering the stock, the most recent being HC Wainwright and Oppenheimer, reiterating their buy calls with price targets of $10 and $11, respectively. The figures mark upsides of 91.94 percent and 111.13 percent from its latest closing price, signaling a highly optimistic outlook for the stock.

READ NEXT: Billionaire Stanley Druckenmiller’s New AI Warning and Top 10 Stock Picks

Follow Insider Monkey on Google News.